Hypolipemiant besides antileukemic effect of imatinib mesylate

被引：16

作者：

Gologan, Radu ^{[1
]}

Constantinescu, Gabriela

Georgescu, Daniela ^{[1
]}

Ostroveanu, Daniela ^{[1
]}

Vasilache, Didona ^{[1
]}

Dobrea, Camelia ^{[1
]}

Iancu, Daniela ^{[1
]}

Popov, Viola ^{[2
]}

机构：

[1] Fundeni Clin Inst, Ctr Hematol & Bone Marrow Transplantat, Bucharest 022328, Romania

[2] Cty Hosp Pitesti AG, Pitesti, Romania

来源：

LEUKEMIA RESEARCH | 2009年 / 33卷 / 09期

关键词：

Chronic myeloid leukemia; Imatinib mesylate; Hypolipemiant and antidiabetic effect; THERAPY; BONE;

D O I：

10.1016/j.leukres.2009.02.024

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The use of imatinib mesylate (IM) (Gleevec, Novartis) in chronic myeloid leukemia (CML) and other neoplastic disorders is in a dramatic increase, inducing long-standing survival. Therefore, the interest in the associated events with this treatment is more and more manifest. We describe a case of CML in which, at the usual antileukemic dose, IM induced a rapid and persistent normalization of the levels of serum cholesterol, triglycerides, low- and high-density lipoproteins and glucose. In the present case report we confirm other observations on the hypolipemiant and antidiabetic effects, concomitant with that antileukemic, of IM. (C) 2009 Elsevier Ltd. All rights reserved.

引用

页码：1285 / 1287

页数：3

共 8 条

[1] Altered bone and mineral metabolism in patients receiving imatinib mesylate
Berman, E
Nicolaides, M
Maki, RG
Fleisher, M
Chanel, S
Scheu, K
Wilson, BA
Heller, G
Sauter, NP
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (19) : 2006 - 2013
[2] Imatinib as a potential antiresorptive therapy for bone disease
Dewar, Andrea L.
Farrugia, Amanda N.
Condina, Mark R.
To, L. Bik
Hughes, Timothy P.
Vernon-Roberts, Barrie
Zannettino, Andrew C. W.
[J]. BLOOD, 2006, 107 (11) : 4334 - 4337
[3] Long-term imatinib therapy promotes bone formation in CML patients
Fitter, Stephen
Dewar, Andrea L.
Kostakis, Panagiota
To, L. Bik
Hughes, Timothy P.
Roberts, Marion M.
Lynch, Kevin
Vernon-Roberts, Barrie
Zannettino, Andrew C. W.
[J]. BLOOD, 2008, 111 (05) : 2538 - 2547
[4] Imatinib and hyperlipidemia
Gottardi, M
Manzato, E
Gherlinzoni, F
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (25) : 2722 - 2723
[5] Tyrosine kinases as targets for cancer therapy
Krause, DS
Van Etten, RA
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (02) : 172 - 187
[6] Imatinib attenuates diabetes-associated atherosclerosis
Lassila, M
Allen, TJ
Cao, ZM
Thallas, V
Jandeleit-Dahm, KA
Candido, R
Cooper, ME
[J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2004, 24 (05) : 935 - 942
[7] TIBULIO D, 2008, P 13 C EUR HEM ASS
[8] Veneri D, 2005, NEW ENGL J MED, V352, P1049, DOI 10.1056/NEJM200503103521023

← 1 →